Emend and Zevalin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emend (aprepitant) and Zevalin (ibritumomab tiuxetan). Common drug interactions include cholestasis among females and pancytopenia among males.

The phase IV clinical study analyzes what interactions people have when they take Emend and Zevalin. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.

What is Zevalin?

Zevalin has active ingredients of ibritumomab tiuxetan. eHealthMe is studying from 2,258 Zevalin users. Check the latest studies of Zevalin.

On Jul, 08, 2026

16 people who take Emend and Zevalin together, and have interactions are studied.

What are the common drug interactions of Emend and Zevalin, by gender? *:

female:

Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
Diarrhoea
Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
Generalised oedema (swelling all over the body)
Stomatitis (inflammation of mucous membrane of mouth)
Transaminases increased
Venoocclusive disease (small veins in the liver are obstructed)
Vomiting
Fluid retention (an abnormal accumulation of fluid in the blood)
Pyelonephritis acute (sudden inflammation of kidney caused by bacteria)

male:

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
Cardiac disorder
Clostridial infection (infectious conditions by clostridium bacteria)
Device related infection
Hyperthermia (body temperature greatly above normal)
Oxygen saturation decreased
Pyrexia (fever)
Stem cell transplant
Aspergillosis (an infection caused by a fungus called aspergillus)

What are the common drug interactions of Emend and Zevalin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Device related infection
Febrile neutropenia (fever with reduced white blood cells)

40-49:

n/a

50-59:

Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
Diarrhoea
Escherichia infection (bacterial infection by escherichia coli)
Hepatosplenomegaly (enlargement of both the liver and the spleen)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Aplasia (defective development or congenital absence of an organ or tissue)
Culture stool positive
Febrile neutropenia (fever with reduced white blood cells)
Respiratory syncytial virus infection (viral disease of respiratory system)
Pyelonephritis acute (sudden inflammation of kidney caused by bacteria)

60+:

n/a

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 4 people, 25.00%
Nausea And Vomiting: 4 people, 25.00%
Bone Marrow Conditioning Regimen: 3 people, 18.75%
Nodal Marginal Zone B-Cell Lymphoma (a type of blood cancer occurs within the lymph nodes): 2 people, 12.50%
Fever: 2 people, 12.50%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 12.50%
Mucosal Inflammation (infection of mucous membrane): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Emend and Zevalin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously